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A pathogenic role of plasmacytoid dendritic cells in
autoimmunity and chronic viral infection
Franck J. Barrat1,2 and Lishan Su3
Following the discovery of plasmacytoid dendritic cells (pDCs) and of their extraordinary ability to produce type I IFNs (IFN-I) 
in response to TLR7 and TLR9 stimulation, it is assumed that their main function is to participate in the antiviral response. There 
is increasing evidence suggesting that pDCs and/or IFN-I can also have a detrimental role in a number of inflammatory and 
autoimmune diseases, in the context of chronic viral infections and in cancers. Whether these cells should be targeted in 
patients and how much of their biology is connected to IFN-I production remains unclear and is discussed here.
Introduction
The existence in the blood of cells with high capacity to secrete
type I IFN (IFN-I) was first documented in the 1950s (Lennert
and Remmele, 1958). It was only in the late 1990s and early
2000s that these IFN-producing cells were defined and charac-
terized in both humans and mice and called plasmacytoid den-
dritic cell (pDC) precursors (Cella et al., 1999; Siegal et al., 1999;
Asselin-Paturel et al., 2001; Nakano et al., 2001). The extraor-
dinary ability to secrete IFN-I by pDCs has driven most of our
understanding about the biology of these cells, in particular how
they participate in antiviral immunity and their adjuvant
properties via the IFN-dependent activation of many innate and
adaptive immune cells. Indeed, depletion of pDCs in mice either
by targeted toxin (Swiecki et al., 2010) or E2-2 mutations
(Cervantes-Barragan et al., 2012) leads to uncontrolled viral in-
fections. Following their stimulation, these cells mature quickly
from a plasmacytoid morphology into a more classic DC with the
associated antigen presentation capability. These cells then stop
producing IFN-I (Duramad et al., 2003; Colonna et al., 2004;
Ito et al., 2006) and can then activate T cells, becoming key
players in the adaptive response. The role of pDCs in linking
innate and adaptive immunity to control viral infections has
been well documented and reviewed (Colonna et al., 2004;
Reizis, 2019). Because of their ability to contribute to both
innate and adaptive responses, pDCs have been a cell type of
great interest (Reizis et al., 2011), and numerous trials are
underway to activate these cells in various disease indications
(Reizis, 2019). However, there is strong evidence, although
much of it indirect, that persistent or uncontrolled activation
of pDCs through the nucleic acid–sensing TLRs contributes to
a number of inflammatory and autoimmune diseases, in-
cluding cancers, as well as in the context of chronic viral in-
fections, and strategies to inhibit these cells are being tested
in clinical trials (Table 1).
A key question that has raised significant debate is howmuch
of the contribution by pDCs to immunity and/or diseases is
solely due to their production of IFN-I. This is a timely question
as many drugs targeting either the IFN pathway or pDCs directly
are currently being evaluated in large clinical trials with various
amounts of success (Table 1). The discovery and initial charac-
terization of pDCs have been discussed in multiple review ar-
ticles (Liu, 2005; Guiducci et al., 2009; Tang et al., 2010; Reizis
et al., 2011; Vermi et al., 2011; Swiecki and Colonna, 2015; Reizis,
2019), so we will focus on discussing the role that they may play
in promoting autoimmunity and then describe novel findings
linking pDC activation and IFN-I production during chronic
infectious diseases. We will also summarize the various ap-
proaches currently in clinical development that target pDCs or
the IFN-I pathway, and discuss how much extrapolation can be
made from recent clinical trials targeting IFN-I.
pDCs, a key cell type that links innate and adaptive immunity
pDCs have a unique role in linking innate and adaptive immu-
nity. These cells have a lymphoid shape and a plasma cell mor-
phology with an extensive endoplasmic reticulum, multiple
mitochondria, and a small Golgi apparatus. pDCs have poor an-
tigen presentation ability, in particular for exogenous antigens,
but can acquire antigen-presenting cell function following ac-
tivation with the expression of co-stimulatory molecules that
can instruct T cells toward specific functional subsets. It is worth
noting that phenotypemapping of human DCs suggests potential
heterogeneity within the described pDC subset (Alca´ntara-
Herna´ndez et al., 2017; Reizis, 2019), and current markers
used to identify and purify pDCs in human blood are shared by a
small population of preDC that can evolve into classical DCs and
may thus account for some of the observations made with pDCs
(See et al., 2017). However, once activated by TLRs, the ex-
pression of co-stimulatory molecules is induced in all pDCs,
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Table 1. Therapeutic approaches targeting the IFN/pDC pathway
Approach Target Drug (name) Company Indication Status
pDC depletion/
inhibition
ILT7 VIB7734 Viela Bio Myositis Active
BDCA2 BIIB-059 Biogen SLE, cutaneous LE Active
CD123 and CD3 XmAb-14045 Xencor AML Active
CD123 IMGN632 Immunogen AML, BPDCN, MDS, B-cell acute
lymphocytic leukemia, and other CD123-
positive malignancies
Active
CD123 Talacotuzumab Johnson & Johnson MDS, LE, systemic cancer, AML Active
CD123 and CD3 Flotetuzumab MacroGenics AML and MDS Active
CD123 Elzonris (tagraxofusp) Stemline
Therapeutics, Inc.
BPDCN, AML, CMML, chronic MF,
multiple myeloma in combination with
pomalidomide
Approved by the FDA in
2018, for the treatment of
BPDCN
IFN pathway IFNAR1 MEDI546, anifrolumab AstraZeneca/
MedImmune
SLE Active
IFN-α MEDI545, sifalimumab AstraZeneca/
MedImmune
SLE, dermatomyositis, and polymyositis Inactive
IFN-α IFNa Kinoid Neovacs SLE, dermatomyositis, type I diabetes,
HIV/AIDS
Active
IFN-α and IFN-
ω
JNJ-0839, JNJ-
55920839
Johnson & Johnson SLE Active
IFN-β PF-06823859 Pfizer Inc. Dermatomyositis, SLE Active
IFN-I
antagonist
RSLV-601 Resolve Preclinical autoimmune Active
Tyk2 BMS-986165 Bristol Myers Squibb
Co.
SLE, psoriasis, Crohn’s disease Active
Tyk2 NDI-031232, NDI-
031301, NDI-031407
Nimbus Therapeutics
LLC
Preclinical Possibly inactive; new
allosteric inhibitors in
development
Tyk2/JAK-1 PF-06700841 Pfizer Inc. Ulcerative colitis, plaque psoriasis, and
alopecia areata
Active
Tyk2/JAK-1 SAR-20347 Sareum Holdings plc/
SRI International
IBD, MS, SLE, psoriasis, RA Active
JAK-3/JAK-1 Tofacitinib Pfizer Inc. RA, psoriatic arthritis, ulcerative colitis,
ankylosis spondylitis, juvenile arthritis,
dry eye syndrome
Active
JAK kinase Baricitinib Eli Lilly RA, atopic eczema, SLE, GVHD, psoriatic
arthritis, alopecia areata
Active
Nucleic acid
sensors
STING
antagonist
TBD Nimbus Therapeutics
LLC/Cellgen
SLE, interferonopathies Active
TLR7/9
antagonist
IMO-3100 Idera Psoriasis Active
TLR7/8/9
antagonist
IMO-8400 Idera Cancer: Waldenstro¨m’s;
DLBCLMyD88(L265P); psoriasis
Active
TLR7/9
antagonist
DV1179 Dynavax SLE Inactive
Immune
complex
digestion
RNA/immune
complexes
RSLV-132 Resolve SLE, Sjogren’s syndrome Active
AML, acute myeloid leukemia; BPDCN, blastic pDC neoplasm; CMML, chronic myelomonocytic leukemia; FDA, US Food and Drug Administration; GVHD, graft-
versus-host disease; IBD, inflammatory bowel disease; LE, lupus erythematosus; MDS, myelodysplastic syndrome; MF, myelofibrosis; MS, multiple sclerosis;
RA, rheumatoid arthritis; TBD, to be determined.
(Friedberg et al., 2005), whereas the TLR9 response in the
mouse is predominantly IL-12, IL-6, etc. One should thus be
careful in extrapolating data gathered studying the mouse pDC
biology to that in humans. Human pDCs can develop in hu-
manized mice with normal phenotype and function in lymphoid
organs (Zhang et al., 2011), which could prove to be relevant to
studying human pDC biology in vivo.
Although pDCs clearly contribute to early antiviral immu-
nity, it is important to distinguish their impact in acute versus
chronic situations. The activation of pDCs and the production of
IFN-I can be important to the antiviral response and can pro-
mote tissue repair. However, the chronic or long-term persistent
activation of these cells, which can be seen in autoimmunity and
persistent viral infections, can lead or contribute to impaired
immunity and disease progression, as discussed below.
pDCs are chronically activated in patients with autoimmunity
and contribute to disease pathogenesis
The contribution of IFN-I to mediating immune responses to in-
fections has been well documented (McNab et al., 2015). In the late
1970s and early 1980s, a series of studies discovered increased levels
of IFN-α in the sera of lupus patients (Hooks et al., 1979; Ytterberg
and Schnitzer, 1982). The chronic presence of elevated levels of IFN-
α in lupus and multiple autoimmune diseases has since been well
documented (Baechler et al., 2003; Bennett et al., 2003; Kirou et al.,
2004; Banchereau et al., 2016), and it is believed that chronic high
levels of IFN-I can contribute to autoimmunity (Crow et al., 2019).
The two critical questions relevant to the development of efficacious
therapeutic strategies appear to be: (1)what biological effect of IFN-I
can explain the promotion of autoimmunity? and (2) what are the
signaling pathways involved leading to IFN production and the
cellular origin of IFN-I in patients?
Biological impact of IFN-I in autoimmune disease
IFN-I has pleiotropic activities and can impact almost every cell
type in the body. IFN-I consists of 13 IFN-α subtypes, IFN-β, IFN-
ω, IFN-κ, and IFN-ε, and it is still unclear how the effect of these
various IFNs differs on immune and/or nonimmune functions
and whether this large number of genes reflects strong evolu-
tionary pressures on the IFN pathway due to its role in antiviral
immunity or underlines different biological functions. The
presence of an IFN-I signature with chronic expression of ISGs is
a hallmark of many autoimmune diseases, which is both striking
and somewhat confusing. Indeed, it is difficult to rationalize
how a common IFN-I–dependent inflammatory response can
yield diseases that have very different clinical manifestations.
One potential explanation is that IFNs act as adjuvants to elevate
the level of inflammation in patients, thus promoting an un-
derlying preexisting immune response to autoantigens (Fig. 1).
The direct effect of IFNs on most immune cells, such as T cell
differentiation and B cell activation and differentiation into
plasma cells (Jego et al., 2003; Rodero and Crow, 2016; Crow
et al., 2019), and on the myeloid cell compartment certainly
argues for this hypothesis (Fig. 1). IFN-induced epigenetic
modifications leading to increased immune activation likely play
a role as well (Park et al., 2017). However, some of the commonly
measured ISGs are extremely sensitive to IFN, and the ease of
which confers T cell priming properties to these cells (Duramad 
et al., 2003; Guiducci et al., 2006). Although pDCs can be acti-
vated through different cell surface receptors and cytosolic nu-
cleic acid sensors (Kim et al., 2010), the sensing of nucleic acids 
through TLR7 and TLR9 seems to be the dominant mode of ac-
tivation of these cells with respect to IFN production (Liu, 2005; 
Guiducci et al., 2009; Swiecki and Colonna, 2015; Reizis, 2019). 
Signaling through these two TLRs leads to the rapid and massive 
production of all type I and type III IFNs, which triggers the 
induction of IFN-stimulated genes (ISGs), many of them with 
antiviral properties. Remarkably, within 10 h following the 
sensing of nucleic acids, >80% of all induced genes in pDCs are 
IFNs or ISGs (Duramad et al., 2003; Ito et al., 2006).
Because of these properties, it is postulated that the key 
function of pDCs is to act as antiviral cells. Consistently, pDCs 
have been reported to play a critical role in controlling early 
virus infections, as summarized in a number of reviews over the 
years (Colonna et al., 2004; Reizis, 2019). It is clear, however, 
that pDCs constitute only one of the many layers involved in 
antiviral responses (Wang et al., 2011). Because of their signifi-
cant evolutionary pressure on the immune system, viruses can 
be sensed by a series of nucleic acid sensors, as well as through 
other pathways, that are present in most cells, including non-
immune cells. It has been extensively reported that IFN-I, in 
particular IFN-β, can be produced by most cell types, such as 
epithelial cells, in response to multiple pathogen-sensing re-
ceptors including TLRs, NOD-like receptors (NLRs), RIG-I–like 
receptors (RLRs), and cyclic GMP-AMP synthase (cGAS)/stim-
ulator of interferon genes (STING), as reviewed recently 
(Ioannidis et al., 2013; Tan et al., 2018; Ablasser and Chen, 2019; 
Swanson et al., 2019). Interestingly, although potentially dam-
aging mutations in nucleic acid–sensing TLRs are extremely rare 
as compared with the other cell surface TLRs (Barreiro et al., 
2009; Casanova et al., 2011), patients with mutations in key el-
ements of the TLR signaling pathways such as MyD88 or IRAK4 
whose pDCs do not produce IFN in response to TLR7 or TLR9, do 
not show drastic susceptibility to viruses (Yang et al., 2005; Ku 
et al., 2007; von Bernuth et al., 2008). These findings suggest 
that immunity to most viruses does not depend solely on pDCs or 
on the TLR7/TLR9-MyD88-IRAK4 pathway (von Bernuth et al., 
2012).
One of the key challenges with our ability to characterize the 
role of pDCs in vivo results from the inherent differences be-
tween human pDCs and their mouse counterpart. Two differ-
ences are particularly problematic. First, while the expression of 
TLR7 and TLR9 is restricted mostly to pDCs and B cells in human 
blood cells, these two TLRs are also expressed by most of the 
myeloid cells in the mouse (Hattermann et al., 2007; Forsbach 
et al., 2008; Janke et al., 2009; Guiducci et al., 2013), which 
contributes to some of the key differences observed between 
mice and humans. Second, although mouse pDCs can produce 
IFN-I and contribute to antiviral response (Boonstra et al., 2003; 
Asselin-Paturel et al., 2005; Reizis, 2019), these cells also pro-
duce pro-inflammatory cytokines such as IL-12 in quantities 
unseen in human pDCs (Boonstra et al., 2003; Duramad et al., 
2003). The consequence of these differences is that the in vivo 
activation of TLR9 in humans yields a very strong IFN-I 
response
The role of TLR7 and TLR9 has been particularly well studied
because of their expression on pDCs, but also due to the ability of
nucleic acid–containing immune complexes to induce IFN by
human pDCs through these two receptors (Fig. 1; Barrat et al.,
2005; Means et al., 2005; Vollmer et al., 2005). Furthermore, the
observation that lupus patients treated with a high dose of
glucocorticoids still express an IFN signature due to survival
signals in pDCs via TLR7 and TLR9 clearly suggests that pDCs are
an important cell type involved in the sustained IFN levels in
patients (Guiducci et al., 2010a), although these data do not
formally exclude the possibility that other cells could contribute
to the IFN, as glucocorticoids have pleiotropic activities. The
contribution of pDCs to disease has also been clearly demon-
strated in multiple mouse models of lupus using genetic ap-
proaches (Rowland et al., 2014; Sisirak et al., 2014), further
suggesting a critical role of pDCs in lupus. The presence of pDCs
in patients’ skin has also been described in a series of related
cutaneous autoimmune diseases including lichen planus, der-
matomyositis, lichen sclerosis, and cutaneous graft-versus-host
disease, which share a common pathological feature named
“interface dermatitis” (Wenzel and Tüting, 2008). The close as-
sociation between IFN-producing pDCs and granzyme B–positive
Figure 1. The central role of pDCs and the produced IFN-I in promoting inflammatory and autoimmune diseases. IFN-I and IFN-III are produced by pDCs
in response to signals delivered by TLR7 and/or TLR9 in response to the sensing of self–nucleic acids. The accumulation of self-DNA and -RNA in the en-
dosomes can be mediated by complexing with antimicrobial peptides, often induced by tissue injury, by anti–double stranded DNA (dsDNA)/anti–small nuclear
ribonucleoproteins (snRNP) or via the uptake of DNA released by NETosis. The secreted IFN will promote the induction of many ISGs and will directly impact
immune cells to promote the generation of autoantibody-producing plasma cells and autoreactive T cells. Mo, monocyte; NET, neutrophil extracellular traps.
detection might mask the fact that most of the ISGs cannot easily 
be functionally connected to autoimmunity.
Origin and source of IFN-I in patients
Although it is likely that the IFN response in patients with au-
toimmune diseases is due to difficulties in controlling or regu-
lating immune responses to nucleic acids (Barrat et al., 2016), the 
identity of the cells responsible for the elevated levels of IFN-I 
during autoimmune diseases is unclear, and the key sensors 
and/or receptors that trigger IFN in these cells are also not well 
defined. Many genetic studies have identified mutations in 
DNase or genes associated with DNA and/or RNA recognition in 
patients with lupus-like syndrome or clearly defined interfer-
onopathies such as Aicardi-Goutières syndrome (Rodero and 
Crow, 2016). This is also consistent with numerous mouse 
studies where deletion of nucleic acid sensors can ameliorate 
autoimmune diseases. It is worth noting, however, that the data 
are not consistent across the models tested, and mice deficient 
for the TLR9 gene surprisingly show exacerbated disease in 
many mouse models of lupus, even though the level of anti–
double stranded DNA autoantibodies can in some cases be de-
creased (Christensen et al., 2006; Sindhava et al., 2017).
HIV-1 genomic RNA is recognized by TLR7, leading to the sig-
naling cascade to activate IRF7 and the downstream IFN-I genes
(Beignon et al., 2005; O’Brien et al., 2013). Reverse transcription
inhibitors or fusion inhibitors fail to prevent HIV-induced pDC
activation. When CD4 binding is blocked with mAb, sCD4, or
anti-CD4 mAb, or when inhibitors of endocytosis are used, HIV-
mediated pDC activation is efficiently abrogated (Reszka-Blanco
et al., 2015). Therefore, CD4-mediated endocytosis of HIV-1 is
sufficient to activate human pDCs via the TLR7 receptor in the
endosome (Fig. 2). Not surprisingly, the co-receptor CCR5 or
CXCR4 is not required for the process. Interestingly, CD4 seems
to deliver HIV-1 virions or RNA to a unique site in the early
endosome, where it preferentially and persistently activates
IFN-I expression (O’Brien et al., 2016).
Regarding its role in controlling early HIV-1 or simian im-
munodeficient virus (SIV) infection in vivo, a number of cor-
relative studies have been reported that indicate their
immediate and efficient activation during acute infection,
correlated with early induction of IFN-I and elevation of ISGs
(Lore´ et al., 2005; Killian et al., 2006; Fitzgerald-Bocarsly and
Jacobs, 2010; Lehmann et al., 2010). However, several reports
also indicate that pDCs are activated during early HIV/SIV in-
fection to recruit HIV/SIV target T cells to the gut to promote
early HIV/SIV infection (Reeves et al., 2012; Lehmann et al.,
2014). Due to the intrinsic limitations of mechanistic investi-
gation in HIV-infected humans or in SIV-infected nonhuman
primates (NHPs), most correlations are established between
HIV or SIV infection and pDC activation in various tissues.
Their exact role in controlling or promoting HIV or SIV infec-
tion in vivo is not clearly defined.
Humanized mice transplanted with human immune tissues
or cells have been developed to study HIV-1 infection (McCune
et al., 1988, 1991; Namikawa et al., 1988; Bonyhadi et al., 1993).
We and others have reported that human pDCs with normal
percentage and function are developed in lymphoid tissues in
humanized mice (Traggiai et al., 2004; Zhang et al., 2011; Tanaka
et al., 2012). Importantly, HIV-1 infection results in T cell de-
pletion, correlated with immune activation in lymphoid organs
of humanized mice as in human patients (Zhang et al., 2011).
Human pDCs are rapidly activated by HIV-1 infection, and the
level of pDC activation is correlated with CD4+ T cell depletion
(Zhang et al., 2011), which is consistent with the observation
from HIV-1–infected patients (Buimovici-Klein et al., 1983, 1986;
Meier et al., 2009) and SIV-infected monkeys (Campillo-
Gimenez et al., 2010; Harris et al., 2010). An mAb to human
CD303 (BDCA-2) that specifically and efficiently depletes human
pDCs in all lymphoid organs in humanizedmice has been used to
characterize the role of human pDCs in HIV-1 infection and
immunopathogenesis during HIV-1 infection (Li et al., 2014,
2017; Zhang et al., 2015; Zhao et al., 2018). When pDCs were
depleted before infection and during acute HIV-1 infection, HIV-
1 replicated to significantly higher levels in all tissues, and no
IFN-I or ISGs were detected. Remarkably, human CD4 depletion
was reduced by pDC depletion in the presence of higher HIV-
1 viremia. Therefore, pDCs are the major source of IFN-I during
acute HIV-1 infection, which suppress HIV-1 replication but
contribute to CD4 T cell depletion (Li et al., 2014; Cheng et al.,
T cells, together with accumulation of nucleic acid–containing 
immune complex at the junction of dermis and epidermis 
(McCauliffe, 1996), suggests that the chronic presence of pDCs 
producing IFN-α may play a central role in disease development 
(Blomberg et al., 2001; Farkas et al., 2001; Wenzel and Tüting, 
2008). It is tempting to speculate that the infiltration of the skin 
by pDCs and their activation likely by self–nucleic acids is part of 
the natural function of pDCs, leading to rapid secretion of IFN-I, 
which is important for wound healing and for initiating host 
immunity (Gregorio et al., 2010; Guiducci et al., 2010b). How-
ever, the presence of pDCs in the skin weeks after the initial 
injury suggests that these cells become chronically activated, 
leading to pathogenic lesions (Guiducci et al., 2010b). Whether 
the cells are chronically activated in the skin or are recruited to 
the skin over many weeks will be important to understand. The 
contribution of pDCs to psoriasis is less clear, as pDCs and IFN-I 
are not involved in the imiquimod-induced psoriasis model in 
mice (Wohn et al., 2013). However, the role of pDCs and IFN-I 
has been shown in a xenograft model (Nestle et al., 2005) and  
recently in a subset of TNF-treated paradoxical psoriasis patients 
(Conrad et al., 2018), suggesting that pDCs may contribute to 
psoriasis in some patients.
One key question is thus to better understand the factors that 
control the qualitative and quantitative response by pDCs in the 
skin as well as the mechanism responsible for the shutting down 
or resolution of the response in vivo, which we know very little 
about but could create some novel therapeutic approaches. 
Taken together, these studies in diseases with interface der-
matitis as well as recent work in skin fibrosis (Ah Kioon et al., 
2018) suggest that pDCs may have a dominant role in the IFN 
response observed in the skin, and studies aimed at targeting 
pDCs in patients should focus on disease indications that involve 
the skin. Although trials targeting TLRs have yielded inconclu-
sive results, a recent study looking at the attenuation of pDC 
response using an antibody that targets the human pDC-specific 
BDCA2 in systemic lupus erythematosus (SLE) patients suggests 
that pDCs are responsible, at least partially, for the presence of 
the chronic IFN signature in the blood of patients (Furie et al., 
2019). Interestingly, blocking pDCs in these patients had a dra-
matic effect on the skin, with a sustained inhibition of IFN-
inducible markers in the skin of patients that correlated with 
amelioration of symptoms (Furie et al., 2019).
Persistent pDC activation during chronic HIV-1 infection 
Intimate interaction of HIV-1 with pDCs during acute infection 
Interestingly, human pDCs express high levels of CD4, the major 
receptor of HIV-1, and the co-receptors CCR5 and CXCR4 (Siegal 
et al., 1999). Indeed, HIV-1 proviral DNA is detected in HIV-
infected patients’ pDCs (Donaghy et al., 2003; Schmidt et al., 
2004). Productive HIV-1 infection of pDCs is efficient at simi-
lar levels as T cells during acute HIV-1 infection in humanized 
mice in vivo (Zhang et al., 2011). However, pDCs appear to be 
relatively resistant to HIV-1 infection in vitro, suggesting in-
trinsic restriction factors that suppress productive HIV-1 repli-
cation in pDCs in vitro (Bloch et al., 2014). On the other hand, in 
the absence of productive HIV-1 infection, CD4+ pDCs efficiently 
bind and endocytose HIV-1 virions to the endosome, where
patients with a rise in anti–IFN-α antibodies showed a signifi-
cantly lower rate of HIV-1–related diseases (Gringeri et al., 1999).
When pDCs were first characterized in the peripheral blood of
HIV-infected patients, it was reported that pDCs were severely
depleted during HIV-1 infection (Siegal et al., 1999; Soumelis
et al., 2001). Later studies have demonstrated that, following
HIV-1 infection, activated pDCs migrate to lymphoid and in-
flammatory tissues (Lehmann et al., 2010). Persistently acti-
vated pDCs in lymphoid tissues seem to be linked with HIV-
1 disease progression (Liu, 2005; Sabado et al., 2010; Zhang and
Su, 2012; Miller and Bhardwaj, 2013). First, IFN-I and ISG re-
sponses persist in HIV-1 infection and pathogenic SIV infections
in Asian macaque species, but resolve to baseline in nonpatho-
genic SIV infections of sooty mangabeys and African green
monkeys (Bosinger et al., 2009; Jacquelin et al., 2009). Second,
pDCs from sooty mangabeys exhibited more rapid resolution of
IFN-α production in response to SIV than rhesus macaques
(Bosinger et al., 2013) and exerted lower IFN-α response in re-
sponse to TLR triggering (Mandl et al., 2008). Third, HIV-
infected patients who do not exhibit disease despite high
Figure 2. CD4-mediated endocytosis of HIV-1 leads to persistent/repeated IFN-I induction in pDCs. HIV-1/CD4 traffics predominantly to early and
recycling endosomes, where HIV-1 genomic RNA interacts with TLR7 to activate MYD88, NFκB, IRF7, and IFN-I, leading to repeated response to TLR7
stimulation and persistent IFN induction. In contrast, influenza virus is endocytosed further to late endosomes or lysosomes, where the cleaved TLR7* re-
sponds to the flu genomic RNA more rapidly and transiently to activate IRF7 and NFκB. The low pH–induced fusion of flu is critical for flu entry and infection. P,
phosphorylation; E, endosome.
2017a, 2018a; Su, 2019. To define the role of IFN-I in HIV-1 
pathogenesis, blocking IFNAR1 during chronic HIV-1 infection in 
humanized mice also reduced CD4 T cell deletion in the presence 
of higher viral replication (#29750; Cheng et al., 2017a). Con-
sistently, blocking IFN-I signaling in NHP with a recombinant 
human antagonistic IFN-β with IFN-α/β receptor (IFNAR) 
binding activity but diminished IFN-I activity led to elevated SIV 
replication, although elevated SIV diseases were observed dur-
ing later years of infection (Sandler et al., 2014).
pDCs are persistently activated during chronic HIV-1 infection 
Persistent hyperinflammation has been associated with patho-
genesis in HIV-1 and SIV infection, but the underlying cellular 
and molecular effectors remain elusive (Deeks, 2011). In the 
years before highly active antiretroviral therapy (HAART), 
persistent IFN-α production was reported to correlate with 
HIV-1 disease progression, and IFN-α was used as a vaccine to 
induce IFN-α–neutralizing antibodies in HIV-1 patients 
(Gringeri et al., 1999). Although interrupted by the HAART en-
rollment of the trial patients, the subgroup of immunized
reservoir persistence, immunopathogenesis, and therapy, as re-
ported with broadly neutralizing antibodies (Halper-Stromberg
et al., 2014), therapeutic vaccines (Cheng et al., 2018b) and
IFNAR-blocking mAb (Cheng et al., 2017a; Zhen et al., 2017) for
HIV-1 reservoir reduction or elimination.
Human T cells are partly rescued by cART in number in
humanized mice. However, IFNAR blockade is needed to fully
reverse inflammation and T cell exhaustion (PD1/TIM3 induc-
tion) in CD8 T cells. Blocking IFNAR during chronic HIV-1 in-
fection in humanized mice led to complete rescue of T cell
number, reversion of T cell immune exhaustion, and anti-HIV
T cell activity. Most importantly, anti-IFNAR mAb has rescued
anti-HIV T cell immunity (Zhen et al., 2017; Cheng et al., 2018b).
Consequently, HIV-1 reservoirs, as measured by both cell-
associated HIV DNA and cells with infectious HIV-1, are re-
duced in the IFNAR-blocking mice. Furthermore, when cART is
stopped, a significant delay of HIV-1 rebound is observed (Cheng
et al., 2017a). Therefore, pDC depletion or IFNAR blockade
provides a new strategy to reduce or control HIV-1 reservoirs
(Cheng et al., 2017a,b, 2018a; Deeks et al., 2017; Zhen et al., 2017)
(Fig. 3).
Therapeutic approaches targeting the pDC/IFN-I axis
There are multiple therapeutic approaches currently targeting
either one or more IFN-I, their receptors, the TLRs or other
nucleic sensors that can induce IFNs, or the pDCs themselves
(Table 1). Each of these approaches offers some advantages, but
all have limitations as well. The key questions are to understand
(1) whether success or failure of any of these approaches in one
disease would predict the outcome in other related diseases; and
(2) how redundant these pathways are, in particular whether
the outcome of a trial targeting the IFNAR, is predictive of a
pDC-depleting strategy. We would argue that this is not the case
for both questions. As discussed above, it is unclear how the
elevated serum levels of specific IFN-I subtypes or of ISGs can
lead to autoimmune diseases with different affected organs,
different serological markers, and different overall pathogene-
sis. The challenge is thus to determine the direct link between
specific IFN-Is, ISGs, and specific organ damage, and untangle
the direct and dominant contribution of IFN to disease. Fur-
thermore, it is expected that approaches as different as blocking
the JAKs or IFN itself or depleting pDCs would impact the IFN or
host immune responses in such a different way, at the mecha-
nistic level, that it is not possible to translate the efficacy of
drugs targeting one pathway to predict the effect of others.
The recent report that a phase III trial testing the effect of
anifrolumab, an mAb that blocks the IFNAR in SLE, did not meet
its primary endpoint was disappointing news, in particular in
light of the promising data of the phase II trials. Althoughwe still
have much to learn from this and other trials that are still under
way using the IFNAR-blocking antibody, it begs to question as to
how much these data would help predict the impact of a pDC-
targeted approach. First, there are inherent differences in both
strategies. The approach of blocking the IFNAR, which is ex-
pressed in most cells of the body, must assume that the effect
will be partial, as it is improbable to reach a complete block in
every cell at the dose tested. Further data looking at the
plasma virus loads have paradoxically low levels of ISG expres-
sion (Rotger et al., 2011). However, the functional role of pDCs in 
HIV-1 in patients or SIV in monkeys is not clearly defined.
To test the role of persistent pDC activation in HIV-1 diseases, 
several reports have documented efforts to modulate pDC ac-
tivity with endocytosis inhibitors in human patients, or with 
TLR7/9 antagonist or TLR7 agonist in SIV-infected NHP. To 
block pDC endocytosis/activation, HIV-1 patients were treated 
with clinical doses of chloroquine used for treating malaria, with 
unclear effects on HIV-1 diseases (Routy et al., 2015; Jacobson 
et al., 2016). Similar efforts have been made to define the role of 
IFN-I signaling in SIV-infected NHP models. In a recent report, 
administration of recombinant IFN-α in SIV-infected NHP 
treated with HAART showed no significant effect on SIV per-
sistence (Palesch et al., 2018). Similarly, blocking IFN-I induc-
tion with a TLR7/TLR9 antagonist in SIV-infected monkeys 
showed no significant beneficial effect on early SIV infection 
(Kader et al., 2013). A recent study with an mAb that neutralizes 
most IFN-α (but not other IFN-I subtypes) in SIV-infected NHP 
showed only slightly elevated SIV replication but no significant 
effect on T cell function or pathogenesis (Carnathan et al., 2018). 
Although generally interesting, the reported findings regarding 
the role of pDC/IFN-I from HIV-infected patients or SIV-infected 
NHP are not definitive, due to the limitation of reagents and 
experimentation in human and nonhuman primates.
Role of pDC in HIV-1 infection and pathogenesis in humanized mice 
Depletion of pDCs with the anti–BDCA-2 mAb in humanized 
mice could diminish IFN-I production during early HIV-1. Ad-
ditionally, the depletion of pDCs could protect human immune 
cells in the presence of increased HIV-1 replication (Li et al., 
2014; Zhang et al., 2015). To test the role of IFN-I signaling in 
humanized mice with persistent HIV-1 infection, the HIV-1 rep-
lication levels in the IFNAR1-blocked group were also enhanced, 
which is associated with suppression of ISG expression. Inter-
estingly, human T cells were rescued in number and functions in 
anti-IFNAR1 mAb–treated mice. Hence, blocking IFNAR1, like 
pDC depletion (Li et al., 2014; Zhang et al., 2015), also enhanced 
HIV-1 replication but reversed HIV-1 diseases during persistent 
HIV-1 infection in humanized mice (Cheng et al., 2017a,b, 
2018a). When an mAb against IFNAR2 was used in humanized 
mice, however, HIV-1 replication was suppressed, which is as-
sociated with reduced immune hyperactivation (Zhen et al., 
2017). It is not clear how blocking IFNAR1 or IFNAR2 had a 
distinct impact on HIV-1 replication, ISG induction, or immune 
activation. Other factors that are different in the two reports 
also include different HIV-1 isolates and different strains of 
immunodeficient mice.
As in human patients, combination antiretroviral therapy 
(cART) or HAART could efficiently inhibit HIV-1 replication, but 
HIV-1 reservoirs persist and rebound rapidly after cART dis-
continuation (Choudhary et al., 2009; Denton et al., 2012; 
Kalscheuer et al., 2012; Marsden et al., 2012; Cheng et al., 2017a). 
As in HIV-1 patients, cART fails to fully suppress HIV-induced 
inflammation, including ISG induction. When cART is stopped, 
HIV-1 rebounds rapidly to pre-cART levels. Therefore, human-
ized mice provide a highly relevant model to study HIV-1
significantly associated with worse prognosis in survival and
metastasis. In human patients with multiple myeloma, TA-pDCs
are shown to suppress antitumor CD8 T cells, associated with
tumor growth (Chauhan et al., 2009; Ray et al., 2017). Thera-
peutic strategies that eliminate or reprogram TA-pDCs will
likely provide a novel immunotherapeutic approach to treating
human cancers with high levels of TA-pDCs.
Concluding remarks
The contribution by IFN-I produced by pDCs to antiviral im-
munity has been well described. Evidence suggests that similar
pathways may drive the pathogenesis of autoimmune and au-
toinflammatory diseases but also chronic infections and cancer.
Trials targeting the IFNs, their receptor or signaling components
of IFNAR, the nucleic acid sensors, or the pDCs are underway,
and initial results have been mixed. It is possible that a key issue
is that the IFN response in the context of an autoimmune disease
mirrors the situation of antiviral responses where multiple cell
types and pathways are involved, depending on the kinetics of
the response, the organ, the pathogen, or the mode of infection.
This creates a situation where targeting specific organs or
symptoms might be preferable, rather than aiming at reducing
the overall disease. Carefully designed clinical studies targeting
specific sensors or cell types will be required to untangle this
question. The concept of blocking the IFN/pDC axis in chronic
infectious diseases is not intuitive due to the key role of IFN in
antiviral response, but the recent findings in diseases such as
HIV and other diseases with common pathogenic mechanisms of
persistent activation suggest that IFN-I and pDCs play a detri-
mental role. The safety of targeting the IFN pathways should be
carefully evaluated, in particular in patients who often receive
immunosuppressive drugs, and whether the risk/ratio of such
treatment will be to the benefit of patients. Finally, it remains to
be determined whether blocking IFN/pDC will lead to transient
amelioration of symptoms or could lead to a disease-modifying
scenario that would reduce the treatment cycle and the overall
risk of adverse events for patients.
Figure 3. Induction of inflammatory or imma-
ture pDCs (ipDCs) during chronic HIV-1 infec-
tion. HIV-1 activates pDCs via CD4-dependent
endocytosis and HIV-1 RNA-mediated TLR7 activa-
tion (1). Persistent activation of pDCs by HIV-1 leads
to accumulation of ipDCs (2). ipDCs deplete and
impair T cells via unclearly defined IFN-dependent
mechanisms (3). Targeting the ipDC/IFN-I axis can
rescue anti-HIV T cells to help control HIV-1 (4). IPC,
IFN-producing cell; ipDC, immature pDC.
pharmacology of anifrolumab outside blood cells, where the 
effect is by definition maximal, would be very informative. It is 
predicted that targeting pDCs will also lead to a partial effect on 
IFN production, but for different reasons. All the IFN-Is and IFN-
IIIs would be reduced but only from a single source and likely 
following the engagement of the TLRs. Pathways involving other 
nucleic acid sensors in other cells would not be impacted. Sec-
ond, it is abundantly clear that pDCs have many other biological 
functions outside of the IFN that they produce. The kinetics of 
IFN production is very limited to the first hours after TLR 
triggering, and pDCs then exert strong antigen presentation 
capabilities. In addition, pDCs secrete cytokines such as IL-6, 
TNF, and IL-12 and control directly or indirectly the expression 
of many proinflammatory cytokines and chemokines, suggest-
ing that the inhibition or depletion of pDCs could have a wider 
impact than just targeting IFN-I. These cells are also activated 
through other TLR-independent ways and produce critical 
chemokines that help direct the immune response. However, 
their role in the skin appears critical, while their contribution to 
the inflammatory response in other organs is less clear. Thus, 
focusing on the skin to evaluate pDC-targeting drugs would take 
advantage of a strong scientific rationale and less complex 
clinical designs. The recent report showing that attenuation of 
pDCs using BIIB059, a humanized mAb that binds the pDC 
marker BDCA2, led to reduced IFN signals and cellular infiltra-
tion in skin lesions with decreased CLASI-A score (Furie et al., 
2019) is a strong indication that an organ-specific approach with 
a primary focus on the skin may be a promising strategy with 
such drugs. One can argue that pDCs can be defined as “pro-
fessional adjuvant cells,” which would explain the potent adju-
vant effect of CpG-containing oligonucleotides in humans. 
Targeting pDC is thus predicted to impact IFN production but 
importantly to directly inhibit immune responses to auto-
antigens (Fig. 1).
Tumor-associated pDCs (TA-pDCs) are detected in multiple 
human cancers. In human breast cancers (Treilleux et al., 2004) 
and ovarian cancers (Conrad et al., 2012), infiltration of pDCs 
is
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